Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Forge Announces Visible Gold & Continued Porphyry Mineralization at Alotta Project (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Ocular Therapeutix Inc OCUL

Healthcare Biotechnology
Ocular Therapeutix, Inc. is a fully-integrated biopharmaceutical company. AXPAXLI, the Company's investigational product candidate for retinal disease, is an axitinib intravitreal hydrogel based on its ELUTYX bioresorbable hydrogel-based formulation technology. Its pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA, a corticosteroid for the treatment of ocular... see more

Recent & Breaking News (NDAQ:OCUL)

Ocular Therapeutix(TM) to Participate in Clinical Trials at the Summit (CTS) 2025

GlobeNewswire 2 days ago

Ocular Therapeutix(TM) To Close Enrollment This Week for SOL-R, its Second Registrational Trial Evaluating AXPAXLI(TM) in Wet Age-Related Macular Degeneration

GlobeNewswire May 28, 2025

Ocular Therapeutix(TM) to Participate in Upcoming Investor Conferences

GlobeNewswire May 14, 2025

Ocular Therapeutix(TM) Reports First Quarter 2025 Results and Business Highlights

GlobeNewswire May 5, 2025

Ocular Therapeutix(TM) to Participate in Upcoming Investor and Scientific Conferences

GlobeNewswire April 29, 2025

Ocular Therapeutix(TM) to Report First Quarter 2025 Financial Results on May 5, 2025

GlobeNewswire April 28, 2025

Ocular Therapeutix(TM) Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire April 11, 2025

Ocular Therapeutix(TM) to Participate in Two Investor Conferences in April

GlobeNewswire March 31, 2025

Ocular Therapeutix(TM) Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire March 7, 2025

Ocular Therapeutix(TM) Reports Fourth Quarter and Full Year 2024 Results and Business Highlights

GlobeNewswire March 3, 2025

Ocular Therapeutix(TM) to Present at Two Investor Conferences in March

GlobeNewswire February 25, 2025

Ocular Therapeutix(TM) to Report Fourth Quarter and Full Year 2024 Results on March 3, 2025

GlobeNewswire February 24, 2025

Ocular Therapeutix(TM) Announces Upcoming Presentations at the Angiogenesis, Exudation, and Degeneration 2025 Virtual Meeting

GlobeNewswire February 3, 2025

Ocular Therapeutix(TM) Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire January 17, 2025

Ocular Therapeutix(TM) Shares SOL-R Enrollment Progress and Next Steps for AXPAXLI(TM) in NPDR

GlobeNewswire January 14, 2025

Ocular Therapeutix(TM) to Provide Corporate Update During 43rd Annual J.P. Morgan Healthcare Conference Presentation

GlobeNewswire January 8, 2025

Ocular Therapeutix(TM) Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire December 13, 2024

Ocular Therapeutix(TM) to Present at the 43rd Annual J.P. Morgan Healthcare Conference

GlobeNewswire December 10, 2024

Ocular Therapeutix(TM) Announces More Than 300 Subjects Randomized in SOL-1

GlobeNewswire December 2, 2024

Ocular Therapeutix(TM) to Participate in December Investor and Scientific Conferences

GlobeNewswire November 26, 2024